Jeffrey A. Feinstein, MD, MPH

Clinical Focus

• Pediatric Cardiology
• Congenital Heart Defects
• Pulmonary Hypertension
• Pulmonary Vascular Disease
• Pulmonary Vascular Abnormalities

Administrative Appointments

• Director, Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford University Medical Center (2000 - present)
• Associate Director, Pediatric and Congenital Cardiac Catheterization, Stanford University Medical Center (2001 - present)

Professional Education

Graduate & Fellowship Program Affiliations

• Pediatrics
• Bioengineering

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Research Interests

Research interests include (1) computer simulation and modeling of cardiovascular physiology with specific attention paid to congenital heart disease and its treatment, (2) development and testing of transcatheter therapies for the treatment of congenital heart disease, and (3) the evaluation and treatment of pulmonary hypertension/pulmonary vascular disease.

In the area of computational modeling, projects are underway in three areas: (1) examination of alterations in blood flow and vessel mechanics caused by coarctation (narrowing) of the aorta and the use of computational modeling to compare surgical and transcatheter methods of treatment, (2) creation of a computational model of the entire pulmonary vascular tree and computational modeling of various disease states including pulmonary artery stenosis and pulmonary hypertension as a disease stratification tool and better predict responses to therapy, and (3) the use of computational modeling to examine flow characteristics and energy efficiency at rest and varying degrees of exercise in patients who have undergone total cavopulmonary connection.

Dr. Feinstein serves as the local P.I. for two ongoing multi-center clinical trials, one investigating a new oral therapy for the treatment of pediatric pulmonary hypertension and another comparing surgical treatment with balloon angioplasty or stent placement for treatment of coarctation of the aorta. Three additional clinical trials for which Dr. Feinstein will be the local P.I. are scheduled to begin within the next year.

Clinical Trials

• Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension (TOPP) Recruiting

Publications

• Use of magnetic resonance imaging and computed tomography. Feinstein JA, Gatzoulis MA. Cardiol Young. 2009: 19 Suppl 1 16-22
• Angina associated with left main coronary artery compression in pulmonary hypertension. de Jesus Perez VA, Haddad F, Vagelos RH, Fearon W, Feinstein J, Zamanian RT. J Heart Lung Transplant. 2009; 28 (5): 527-30
• Short- and long-term outcomes of necrotizing enterocolitis in infants with congenital heart disease. Pickard SS, Feinstein JA, Popat RA, Huang L, Dutta S. Pediatrics. 2009; 123 (5): e901-6
• Evaluation, risk stratification, and management of pulmonary hypertension in patients with congenital heart disease. Feinstein JA, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2009: 106-11
• A novel non-invasive method of estimating pulmonary vascular resistance in patients with pulmonary arterial hypertension. Haddad F, Zamanian R, Beraud AS, Schnittger I, Feinstein J, Peterson T, Yang P, Doyle R, Rosenthal D. J Am Soc Echocardiogr. 2009; 22 (5): 523-9